---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-076339"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:52:26.795029+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M

## Summary
- Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.
- Total purchase price $35.1M plus determined cure costs capped at $277,703.63.
- Transaction subject to Bankruptcy Court approval; Eiger filed Chapter 11 on April 1, 2024.
- Deal includes assigned contracts and regulatory filings; closing expected after court order.
- Amylyx deposits $1.755M into escrow as deposit per approved bid procedures.

## SEC filing metadata
- accession: 0000950170-24-076339
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017024076339/0000950170-24-076339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017024076339/amlx-20240621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-076339
- JSON: https://secwatch.observer/filing/0000950170-24-076339.json
- Plain text: https://secwatch.observer/filing/0000950170-24-076339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.